1. Home
  2. Medical News
  3. Modern Aesthetics RMD
advertisement

Letybo Phase 3 Data Show Rapid Improvement in Frown Lines at ASDS 2026

Key Takeaways

  • Phase 3 BLESS III data presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting showed that 64.7% of patients treated with Letybo (letibotulinumtoxinA-wlbg) met the primary improvement endpoint at week 4, compared with 0% receiving placebo.
  • The median time to improvement was 3 days, and no serious treatment-related adverse events were reported in the Phase 3 study.
  • Additional analyses examined outcomes among women aged 35 to 50 years and patient-reported quality of life and satisfaction across three BLESS trials.
Hugel Aesthetics
11/19/2026

New Phase 3 clinical trial data presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting showed improvements in moderate to severe glabellar lines among patients treated with Letybo (letibotulinumtoxinA-wlbg), according to an announcement from manufacturer Hugel Aesthetics.

The findings, presented during the November 5-8 meeting in San Diego, included efficacy, onset of action, and patient-reported outcomes from the BLESS clinical development program.

Letybo is a botulinum toxin type A product approved by the US Food and Drug Administration (FDA) for the temporary improvement of moderate to severe glabellar lines in adults.

BLESS III Trial Results and Patient-Reported Outcomes

In the randomized, double-blind, placebo-controlled Phase 3 BLESS III study, 64.7% of Letybo-treated patients achieved the primary improvement endpoint at week 4, compared with 0% in the placebo group. The median time to improvement was 3 days, and investigators reported no serious treatment-related adverse events.

Michael H. Gold, MD, presented additional post hoc analyses evaluating women aged 35 to 50 years. Up to 87.4% achieved improvement by week 2, while 73.6% had no visible glabellar lines at maximum frown by week 4, corresponding to a score of 0 on the Glabellar Line Scale.

A separate pooled analysis involving 1,272 participants across three BLESS trials evaluated patient-reported outcomes. According to Hugel, the findings showed improvements in quality of life, emotional well-being, and treatment satisfaction compared with placebo.

The company also highlighted its expanding US presence and interest in Korean aesthetic approaches, commonly referred to as K-Aesthetics.

Source

Hugel. Hugel Aesthetics showcases growing U.S. presence, clinical innovation and K-Aesthetic leadership at 2026 ASDS Annual Meeting. PR Newswire. Published November 18, 2026. Accessed November 18, 2026. Read press release

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free